Target Name: OPA3
NCBI ID: G80207
Review Report on OPA3 Target / Biomarker Content of Review Report on OPA3 Target / Biomarker
OPA3
Other Name(s): 3-methylglutaconic aciduria type III | OPA3 outer mitochondrial membrane lipid metabolism regulator | MGC75494 | Optic atrophy 3 (Iraqi-Jewish optic atrophy plus) | OPA3 variant 2 | OPA3 variant 1 | O

Understanding OPA3: A Potential Drug Target for VLFA-related Diseases

OPA3 (3-Methylglutaconic Aciduria Type III) is a rare genetic disorder that affects the metabolism of lipids, which are an essential component of the body. The three-letter name OPA3 refers to the specific genetic mutation that is causing the disorder. This genetic mutation has been identified as a potential drug target or biomarker for the treatment of various diseases, including cardiovascular disease, diabetes, and neurological disorders.

OPA3 is a recessive inherited disorder that is characterized by the accumulation of very long chain acids (VLFA) in the liver and other tissues. The accumulation of VLFA leads to the characteristic symptoms and diagnostic hallmark of OPA3, which include progressive hepatic steatosis, Hepatocellular damage and neuropsychiatric symptoms.

The three-methylglutaconic aciduria type III gene has been identified as the cause of OPA3. The three methyl groups on the gene have been shown to alter the structure and function of the OPA3 protein. The most common genetic variation in OPA3 is a missense mutation, which results in the substitution of a thymine base (T) for a guanine base (G) at position 614. This mutation has been shown to cause the accumulation of VLFA in the liver and other tissues, leading to the characteristic symptoms of OPA3.

OPA3 is a fatty acid oxidation disorder, which means that it is characterized by the inability to properly break down and remove long chain fatty acids from the body. The accumulation of VLFA in the liver and other tissues can cause a range of cellular and tissue problems , including the development of insulin resistance, the risk of cardiovascular disease, and the development of neurodegenerative disorders.

In addition to its association with cardiovascular disease and neurodegenerative disorders, OPA3 is also being investigated as a potential drug target or biomarker for the treatment of other diseases. For example, studies have shown that OPA3 is associated with the development of type 2 diabetes, and that modulating the levels of VLFA in the liver may be a promising strategy for the treatment of this disease.

In addition to its potential therapeutic applications, OPA3 is also an attractive biomarker for the diagnosis and screening of other diseases. The accumulation of VLFA in the liver and other tissues is a well-established hallmark of OPA3, and can be used as a diagnostic marker for this disease. Additionally, the level of VLFA in the liver can be used as a marker for the assessment of disease severity and response to therapeutic intervention.

In conclusion, OPA3 is a rare genetic disorder that is characterized by the accumulation of very long chain fatty acids in the liver and other tissues. The three-letter name OPA3 refers to the specific genetic mutation that is causing the disorder. OPA3 is a potential drug target or biomarker for the treatment of various diseases, including cardiovascular disease, diabetes, and neurological disorders. Further research is needed to fully understand the role of OPA3 in the development and progression of these diseases, as well as its potential as a diagnostic marker and therapeutic target.

Protein Name: Outer Mitochondrial Membrane Lipid Metabolism Regulator OPA3

Functions: May play some role in mitochondrial processes

The "OPA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OPA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1